Shire Plc. Receives Consensus Recommendation of “Buy” from Analysts (NASDAQ:SHPG)
Shire Plc. (NASDAQ:SHPG) has been given an average recommendation of “Buy” by the sixteen brokerages that are covering the company, StockRatingsNetwork reports. Six analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $150.82.
Shire Plc. (NASDAQ:SHPG) traded up 1.07% during mid-day trading on Thursday, hitting $152.84. 91,986 shares of the company’s stock traded hands. Shire Plc. has a 1-year low of $86.01 and a 1-year high of $151.62. The stock’s 50-day moving average is $144.2 and its 200-day moving average is $127.5. The company has a market cap of $27.939 billion and a P/E ratio of 44.06.
A number of research firms have recently commented on SHPG. Analysts at Leerink Swann set a $170.00 price target on shares of Shire Plc. in a research note to investors on Wednesday. Separately, analysts at RBC Capital raised their price target on shares of Shire Plc. from $138.00 to $153.00 in a research note to investors on Tuesday. They now have a “sector perform” rating on the stock. Finally, analysts at Morgan Stanley initiated coverage on shares of Shire Plc. in a research note to investors on Monday, January 27th. They set an “overweight” rating on the stock.
Shire plc (NASDAQ:SHPG) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.